Related Experiment Video
Updated: Feb 1, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Pathological response of ovarian cancer to neoadjuvant chemotherapy
1N.N. Petrov Institute of Oncology, Leningradskaya 68, St.-Petersburg 197758, Russia. shurikiv@mail.ru.
Abstract:
There is only a few of studies devoted to evaluation of pathologic response of ovarian cancer (OC) to neoadjuvant chemotherapy (NACT). Pathologic complete responses (pCR), which are characterized by the lack of viable tumor cells in surgical specimens, are rarely observed in ovarian carcinomas. Multiple reports demonstrate that pCR is associated with evidently improved disease outcomes. Recommendations of the International Collaboration on Cancer Reporting suggest to use recently developed Chemotherapy Response Scoring (CRS) system, which is based on the pathological analysis of surgically removed omental masses. CRS3 (complete or near-complete response) is characterized by the lack of residual tumor cells in the omentum or presence of tumor foci up to 2 mm maximum size. It is observed after NACT in approximately 30-40% patients with high-grade serous ovarian cancer (HGSOC) and is reproducibly associated with the improvement of the disease prognosis.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Ovarian Cycle
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

